Chapter 16 — Key Takeaways

IGF-1, Myostatin Inhibitors, and the Muscle-Building Peptides

The one sentence

A drug that reliably increases muscle mass and does not improve what a person can do is not a successful drug — and in this therapeutic area, that is not a hypothetical failure mode but a repeated, documented one.

How muscle grows

• Hypertrophy is net protein accretion: synthesis exceeding breakdown, integrated over weeks and months. There is no growth switch, only a balance to tilt.
• Mechanical loading is the dominant signal. Satellite cells supply the additional nuclei that substantial fiber growth requires.
• Resistance training is the dominant intervention and no peptide substitutes for it. Everything in this chapter is studied as an adjunct or as a disease therapy.
• Any performance claim here is implicitly a claim about adding something on top of training. That is a much harder thing to demonstrate, and it is almost never what the evidence measured.
• Hypertrophy (bigger fibers) is what adults get. Hyperplasia (more fibers) is largely developmental — remember this at the cattle.

IGF-1

• IGF-1 is a 70-residue polypeptide made largely in the liver in response to GH, mediating many of GH's anabolic effects. It promotes growth and inhibits apoptosis.
• The binding proteins are the physiology. Upward of 99% of circulating IGF-1 is bound; the IGFBP system buffers concentration, extends half-life, restricts distribution, and localizes activity. "Total IGF-1" is not the number that does anything.
• Mecasermin is recombinant human IGF-1, approved for severe primary IGF-1 deficiency in children. Narrow, real, and mechanism-confirming. Its label carries a prominent hypoglycemia warning, because IGF-1 resembles insulin.
• That narrow approval proves the mechanism and does not license performance claims. Replacement in deficiency is not enhancement in sufficiency (Chapter 14).
• IGF-1 LR3 is engineered specifically to escape the binding proteins — that is, to disable a control system. Originally a cell-culture reagent. Unapproved anywhere, known by a code rather than a generic name (Chapter 1 §1.8).

Myostatin and follistatin

• Myostatin (GDF-8) is a negative regulator — a brake — signaling through ActRIIB and Smad2/3.
• Natural loss of function is documented in mice, cattle (double-muscled breeds), dogs, and rare human cases. This is real and striking, and it is the best-supported part of the story.
• A developmental knockout is not adult blockade. The animals developed without the gene through the period when fiber number is set; adults cannot add fibers.
• The animals came with costs: calving difficulty, reduced fertility, tendon and joint problems — and reduced force per unit of cross-section. Bigger, and gram for gram weaker.
• Follistatin binds and inhibits myostatin and activin A, GDF-11, and some BMPs — broad, not selective. It is a glycosylated protein of roughly 35–40 kDa, which makes gray-market product identity a serious open question. Follistatin-344 is unapproved.
• The follistatin gene therapy trials are a different intervention entirely and do not support an injectable product.

The central finding

• Multiple sponsors, multiple molecular strategies, real randomized placebo-controlled trials in muscular dystrophy and other wasting conditions.
• Lean mass increased. Function did not reliably follow. Multiple programs were discontinued.
• The drugs engaged the target. The pharmacology was not the problem. The assumption was.

Mass is a surrogate; function is the outcome

• Four different things: mass → strength → function → independence. Each arrow is a hypothesis requiring its own evidence.
• DXA "lean mass" includes water, glycogen, and connective tissue. Specific force can fall as size rises. Function is limited by whatever is most limiting, which is often not muscle.
• The intuition that mass equals function comes from resistance training, which raises every rung at once. A drug that adds tissue without the stimulus severs the link that made the intuition persuasive.
• Surrogates are legitimate only when validated for the specific intervention and population. Lean mass is not validated for function in muscle-wasting disease — the §16.5 trials were the validation attempt, and it came back negative. Hence functional co-primary endpoints.
• The Chapter 8 pairing: on GLP-1 drugs lean mass falls and function improves; here lean mass rises and function does not. Same principle, opposite directions. Only measurement settles it.

Sarcopenia

• Where a working drug would matter most — falls, fractures, independence, mortality. There is none approved, in the US or Europe.
• The field moved its own definition. Consensus criteria now lead with low muscle strength, use mass as confirmatory, and grade severity by physical performance. The specialty that studies muscle loss demoted mass on its own evidence.
• What works: progressive resistance training with adequate protein. Any drug must show benefit on top of that.

Cancer and growth signaling

• IGF-1 promotes growth and inhibits apoptosis; higher circulating levels are associated with increased risk of several cancers in observational studies.
• Association is not causation; confounding is substantial; no causal claim is established.
• The two natural experiments: acromegaly at the high end (Chapter 14), severe GH receptor deficiency at the low end. Both suggestive, neither decisive.
• The honest conclusion: the risk of chronically elevating this axis in a healthy person is unquantified — which is not the same as small. And risk is only ever weighed against benefit; for the performance claim, the benefit side of the ledger is empty.

The four ratings

Note the two kinds of negative. The ⚠️ is awarded because human data exists and is disappointing — a worse position for a claim than a ❌ awarded for pure absence, despite the friendlier symbol. And the final ❌ is stronger than an ordinary one: the disease trials that ran are evidence against the performance claim, not merely absence of evidence for it.

Dossier — Field 6

What the evidence actually measured. Three cases:

• Case A — surrogate improved, outcome never measured. Claim cannot exceed ⚠️; asserted confidently, usually ❌.
• Case B — surrogate improved, outcome measured, outcome improved. The arrow held.
• Case C — surrogate improved, outcome measured, outcome did not improve. The arrow broke. Worse than Case A, and only Case A can be fixed by running a study.

If you remember five things

1. Mechanism confirmed is not therapy demonstrated. Nine in ten compounds entering human trials never reach approval, and this is what one of those looks like from the inside.
2. Mass, strength, function, and independence are four different things.
3. Mecasermin's approval is narrow by design and licenses nothing beyond itself.
4. A developmental knockout is not adult blockade.
5. Unquantified risk is not small risk — and it is only ever evaluated against a benefit, which here has not been demonstrated.